All In Biotech

Drug Trial Radar · NCT00221104

Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Last checked: Nov 19, 2026Latest source record: Jan 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,578 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,578

Actual

Start

Mar 1, 2004

Primary completion

Jul 2014

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Labour and Welfare, Japan; Hiroshima University
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although hyperlipidemia is not always the risk factor of stroke, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke in the patient with ischemic heart disease. The neuroprotective mechanism beyond cholesterol lowering should be expected to attenuate inflammation and atherosclerosis. The present study hypothesizes if pravastatin prevents recurrent stroke in the ischemic stroke patients with safety.

Conditions

  • Ischemic Stroke

Interventions

  • PravastatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Stroke and TIATime frame: up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hiroshima University

    Hiroshima, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.